Contrast-Enhanced Ultrasound for Kidney Cancer
Trial Summary
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications.
What data supports the effectiveness of the treatment Contrast-Enhanced Ultrasound for Kidney Cancer?
Is contrast-enhanced ultrasound (CEUS) safe for humans?
Contrast-enhanced ultrasound (CEUS) is generally considered safe for humans, as it allows for real-time imaging without affecting kidney function. While specific safety data for humans is not detailed in the provided research, CEUS is a guideline-recommended strategy for diagnosing kidney issues, suggesting its safety is well-regarded in medical practice.25678
How is the treatment Contrast-Enhanced Ultrasound (CEUS) different from other treatments for kidney cancer?
Contrast-Enhanced Ultrasound (CEUS) is unique because it uses sound waves and a special contrast agent to create detailed images of blood flow in kidney tissues, helping to diagnose kidney cancer without the use of ionizing radiation or nephrotoxic agents, making it safer and potentially more cost-effective than traditional imaging methods like CT or MRI.256910
What is the purpose of this trial?
This phase II trial studies how well contrast-enhanced ultrasound (CEUS) works for diagnosing patients with renal cell cancer (RCC) that has come back (recurrent) after an ablation. Diagnostic imaging, such as CEUS, may help find and monitor long term renal cell cancer recurrence following cryo or microwave ablation.
Eligibility Criteria
This trial is for adults who've had kidney cancer treatment with cryo or microwave ablation and need monitoring for recurrence. They must be medically stable, not pregnant if female of child-bearing age, and have had a contrast-enhanced MRI/CT scan recently.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Diagnostic Imaging
Patients receive Lumason IV and undergo CEUS imaging with MRI/CT on study
Follow-up
Participants are monitored for safety and effectiveness after diagnostic imaging
Treatment Details
Interventions
- Contrast-Enhanced Ultrasound
- Sulfur Hexafluoride Lipid Microspheres
Contrast-Enhanced Ultrasound is already approved in European Union, United States for the following indications:
- Diagnosis of renal cell carcinoma
- Monitoring of recurrent renal cell carcinoma
- Diagnosis of renal cell carcinoma
- Monitoring of recurrent renal cell carcinoma
Find a Clinic Near You
Who Is Running the Clinical Trial?
john eisenbrey
Lead Sponsor
Thomas Jefferson University
Lead Sponsor
National Cancer Institute (NCI)
Collaborator